Related Experiment Video
Updated: Jun 15, 2026

In Vitro Microfluidic Disease Model to Study Whole Blood-Endothelial Interactions and Blood Clot Dynamics in Real-Time
Published on: May 24, 2020
Thrombocardiology: an update
1Center for Clinical Heart Research, Department of Cardiology, Oslo University Hospital, Ullevål, Oslo, Norway. harald.arnesen@uus.no
Insights
Thrombocardiology advances balance bleeding and clotting risks. New antithrombotic drugs for acute coronary syndromes and atrial fibrillation stroke prevention were discussed, focusing on efficacy and safety.
Area of Science:
- Cardiology
- Thrombosis Research
Background:
- Thrombocardiology is crucial in modern cardiology, managing risks of thrombotic complications and bleeding.
- Active antithrombotic drugs, while treating conditions like myocardial infarction and stroke, increase bleeding risks.
Purpose of the Study:
- To provide an update on basic mechanisms of thrombosis and bleeding.
- To discuss new and emerging antithrombotic drugs for acute coronary syndromes and long-term prophylaxis.
- To highlight thrombotic mechanisms in atrial fibrillation contributing to stroke.
Main Methods:
- Review of current research and expert discussions from the EuroThrombosis Summit 2009.
- Focus on efficacy and safety profiles of antithrombotic therapies.
- Analysis of thrombotic mechanisms in specific cardiovascular conditions.
Main Results:
- Significant advancements in understanding thrombosis and bleeding.
- Evaluation of existing and pipeline antithrombotic agents.
- Insights into stroke risk factors associated with atrial fibrillation.
Conclusions:
- Ongoing research is vital for balancing antithrombotic efficacy with bleeding safety.
- New drug development is critical for managing complex cardiovascular conditions.
- Understanding specific thrombotic mechanisms improves patient outcomes and stroke prevention.
Abstract:
The field of thrombocardiology, dealing with the delicate balance between thrombotic complications and bleeding, is thought to be increasingly important in modern cardiology. Dramatic thromboembolic complications, such as myocardial infarction and stroke, have stimulated the development of a series of active drugs with inherent predisposition to serious bleeding. The EuroThrombosis Summit 2009 (8-10 October 2009, Oslo, Norway) provided an impressive update from leading authorities and researchers in the field. With the focus on basic mechanisms of thrombosis and bleeding, new antithrombotic drugs on the arena and 'in the pipeline', both for acute coronary syndromes and their long-term prophylaxis, were discussed in relation to efficacy and safety. The thrombotic mechanisms in atrial fibrillation mainly responsible for the threatening complication of stroke were also highlighted.
Related Concept Videos
Venous Thrombosis III: Interprofessional Care
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations
Venous Thrombosis I: Introduction
Anticoagulant Drugs: Low-Molecular-Weight Heparins
Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care
